Skip to content
VG Life Sciences logo — Developing lifesaving therapies for drug-resistant cancers a...

VG Life Sciences

Developing lifesaving therapies for drug-resistant cancers and autoimmune diseases through innovative research and advanced drug technologies.

Founded 1995 Post-IPO Equity Total: $2.79M Biotechnology, Health Care

General Information

Company Name VG Life Sciences
Founded Year 1995
Industries Biotechnology, Health Care
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with VG Life Sciences. To contact VG Life Sciences, visit vglifesciences.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does VG Life Sciences compare?

A PDF of VG Life Sciences and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting VG Life Sciences soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About VG Life Sciences

VG Life Sciences is a biotechnology startup dedicated to developing innovative therapies for drug-resistant cancers and autoimmune diseases. The company's focus on advancing research and development is facilitated by two platform technologies: Targeted Peptide Technology (TPT) and Metabolic Disruption Technology (MDT). The company's flagship drug, VG1177, has shown promising potential, holding a composition-of-matter patent (Patent No: US 8,957,031). VG1177 aims to inhibit the survival of pro-inflammatory cells responsible for autoimmune diseases. Having completed a pre-investigational new drug meeting with the FDA (IND # 110820) and initiated preclinical work in November 2013, VG Life Sciences is making significant strides towards clinical trials. Concurrently, the company is conducting extensive research at the Texas A&M Health Sciences Center laboratory, collaborating with research scientists from various institutions nationwide. In 2013, the company secured a $2.24M Post-IPO Equity investment from MedBridge Venture Fund, underscoring the investor confidence in VG Life Sciences' groundbreaking approach to addressing critical medical challenges. Founded in 1995, VG Life Sciences continues to drive forward in the biotechnology and healthcare industries, poised to make a profound impact with its pioneering drug technologies.

Business keywords: pharmaceuticals, drug development, cancer treatment, autoimmune diseases, therapeutic research, patent technology, clinical trials, preclinical studies, FDA approval, metabolic disruption, peptide technology, innovative therapies, medical innovation

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $2.24M 1
MedBridge Venture Fund
02 Oct 2013
Post IPO Equity $550.00K -
01 Mar 2013

VG Life Sciences Alternatives & Competitors

View All Alternatives
VG Life Sciences vs
Bioniz, LLC
Bioniz, LLC United States

Pioneering the future of autoimmune and cancer treatment with innovative small peptides and molecule...

Acquired
3 employees
Biotechnology, Health Care
VG Life Sciences vs

An emerging biotech discovering & developing novel therapies for cancer and viruses where other opti...

6 employees
Biotechnology, Health Care
VG Life Sciences vs
Quince Therapeutics
Quince Therapeutics United States

Dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases

Post-IPO Equity
25 employees
Biotechnology, Health Care

FAQ About VG Life Sciences

Developing lifesaving therapies for drug-resistant cancers and autoimmune diseases through innovative research and advanced drug technologies.
VG Life Sciences was founded in 1995.
VG Life Sciences operates in Biotechnology and Health Care. Its work centres on pharmaceuticals, drug development, cancer treatment and autoimmune diseases.
VG Life Sciences has completed 2 funding rounds, raising a total of $2.79M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to VG Life Sciences include Bioniz, LLC, Creative BioTherapeutics LLC, Quince Therapeutics, Palatin Technologies, Chase Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
VG Life Sciences and Bioniz, LLC are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for VG Life Sciences, https://bouncewatch.com/company/vg-life-sciences, updated 26 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout